The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma-Reference-Cited by-同舟云学术

The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma

Published:2020-07-29 Issue:554 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Lulla Premal D.¹^ORCID,Tzannou Ifigeneia¹,Vasileiou Spyridoula¹,Carrum George¹,Ramos Carlos A.¹^ORCID,Kamble Rammurti¹,Wang Tao¹,Wu Mengfen¹,Bilgi Mrinalini¹,Gee Adrian P.¹^ORCID,Mukhi Shivani¹,Chung Betty¹^ORCID,Wang Linghua¹^ORCID,Watanabe Ayumi¹,Kuvalekar Manik¹,Jeong Mira¹,Li Yumei¹^ORCID,Ketkar Shamika¹,French-Kim Matthew¹^ORCID,Grilley Bambi¹,Brenner Malcolm K.¹^ORCID,Heslop Helen E.¹^ORCID,Vera Juan F.¹,Leen Ann M.¹^ORCID

Affiliation:

1. Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX 77030, USA.

Abstract

Infusions of autologous T cells specific for multiple tumor antigens were safe and induced responses in some patients with multiple myeloma.

Funder

National Cancer Institute

NIH Clinical Center

American Society of Hematology

Leukemia and Lymphoma Society

Edward P. Evans Foundation

American Society for Blood and Marrow Transplantation

Leukemia texas

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference36 articles.

1. Multiple myeloma

2. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide

3. Current treatment landscape for relapsed and/or refractory multiple myeloma

4. Current Treatment for Multiple Myeloma

5. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients;Blood Advances;2024-09-10

2. KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancer;BMC Cancer;2024-07-07

3. Multiple myeloma: signaling pathways and targeted therapy;Molecular Biomedicine;2024-07-04

4. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia;Blood;2024-04-25

5. Clinical Experiences with TAA ‐T in Lymphoid Malignancies;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21